A Tech Review blog post discusses the work of Richard Lifton, who studies human outliers, so-called "extreme phenotypes" -- including a man with extremely high bone density. Lifton found a link to bone density with a mutation in the LDL-related receptor protein 5 gene and, now, a drug targeting part of that molecular pathway is in clinical testing to treat osteoporosis.